In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Trevi Therapeutics Inc (NASDAQ: TRVI) was $10.98 for the day, down -3.35% from the previous closing price of $11.36. In other words, the price has decreased by -$3.35 from its previous closing price. On the day, 2.04 million shares were traded. TRVI stock price reached its highest trading level at $11.807 during the session, while it also had its lowest trading level at $10.58.
Ratios:
Our analysis of TRVI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 21.93 and its Current Ratio is at 21.93. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Leerink Partners on November 13, 2025, initiated with a Outperform rating and assigned the stock a target price of $13.
On August 21, 2025, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $18.
On July 01, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $25.Cantor Fitzgerald initiated its Overweight rating on July 01, 2025, with a $25 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 07 ’25 when Delfini Lisa bought 108,650 shares for $9.50 per share.
Delfini Lisa bought 40,000 shares of TRVI for $386,716 on Oct 03 ’25. On Aug 27 ’25, another insider, Delfini Lisa, who serves as the Officer of the company, bought 312,855 shares for $8.09 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRVI now has a Market Capitalization of 1407966848 and an Enterprise Value of 1213862912.
Stock Price History:
The Beta on a monthly basis for TRVI is 0.96, which has changed by 1.8188586 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, TRVI has reached a high of $14.39, while it has fallen to a 52-week low of $3.47. The 50-Day Moving Average of the stock is -8.72%, while the 200-Day Moving Average is calculated to be 30.35%.
Shares Statistics:
TRVI traded an average of 1.84M shares per day over the past three months and 1355240 shares per day over the past ten days. A total of 128.22M shares are outstanding, with a floating share count of 83.78M. Insiders hold about 34.67% of the company’s shares, while institutions hold 69.49% stake in the company. Shares short for TRVI as of 1765756800 were 13651656 with a Short Ratio of 7.42, compared to 1763078400 on 14784433. Therefore, it implies a Short% of Shares Outstanding of 13651656 and a Short% of Float of 12.24.
Earnings Estimates
A detailed examination of Trevi Therapeutics Inc (TRVI) is currently in progress, with 8.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.09 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.35 and -$0.4 for the fiscal current year, implying an average EPS of -$0.37. EPS for the following year is -$0.47, with 8.0 analysts recommending between -$0.22 and -$0.66.
